Mode
Text Size
Log in / Sign up

Heparin separator residual plasma shows concordance with standard tubes for cfDNA analysis in feasibility studyStudy explores using leftover hospital blood plasma for DNA biobanking

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider residual heparin separator plasma as a potential cfDNA source, but evidence is from a small observational study.

This cohort study evaluated the feasibility of using residual plasma from heparin separators—tubes typically used for clinical chemistry tests—as a source for circulating cell-free DNA (cfDNA) biobanking and analysis. The study involved two groups: healthy volunteers (n=5 for immediate-processing comparisons; n=6 for clinical-handling simulations) and a Hospital Cohort of 38 viral PCR-positive patients. The heparin separator plasma was compared against standard cfDNA collection tubes (EDTA and Streck plasma) across several molecular features.

In healthy volunteers under immediate processing, methylation patterns and fragmentation features showed high concordance between heparin and standard tubes (Spearman's ρ=0.65-0.70, n=5). In a clinical-handling simulation with 6 volunteers, cfDNA integrity in heparin separators was comparable to EDTA plasma. In the 38-patient Hospital Cohort, viral detection showed strong concordance (Spearman's ρ=0.95). For a subset of these patients, copy number alteration profiling (n=6) and methylation patterns (n=12) also showed strong to moderate concordance (Spearman's ρ=0.50-0.96).

Safety and tolerability data were not reported. Key limitations include the observational design, small sample sizes for specific analyses, and lack of reported p-values or confidence intervals for correlation measures. The practice relevance is restrained: the study suggests hospital residual plasma, if processed within a short pre-centrifugation window and refrigerated, could represent an untapped resource for cfDNA biobanking. However, this is a proof-of-concept finding based on correlation in specific cohorts and does not establish clinical utility or efficacy for diagnostic testing.

Researchers wanted to see if leftover plasma from common hospital blood tests could be a good source for collecting and studying cell-free DNA (cfDNA). cfDNA is genetic material that floats freely in the blood and can provide information about health. The study used plasma from standard 'heparin separator' tubes, which are often discarded after routine tests, and compared it to plasma from tubes specifically designed for DNA collection.

The study involved two small groups: 5-6 healthy volunteers and 38 hospital patients who tested positive for a virus. They looked at several features of the DNA, including its patterns and ability to detect viruses. In both groups, the DNA from the leftover heparin plasma showed strong similarity to the DNA from the special collection tubes when processed quickly.

No safety issues were reported, as the study was analyzing already-collected samples. The main reason for caution is that this was a small, observational study designed to see if this approach is possible. The results are based on statistical correlations from limited groups of people.

Readers should understand this research shows a potential new source for biobanking DNA that is already available in hospitals. It does not mean this method is ready for clinical use. Much larger studies are needed to confirm these early findings and see how well it works for different types of medical testing.

What this means for you:
Early study finds leftover hospital blood plasma may be usable for DNA research, but more confirmation is needed.

Study Details

Study typeCohort
Sample sizen = 5
EvidenceLevel 3
PublishedMar 2026
View Original Abstract ↓
BACKGROUNDCirculating cell-free DNA (cfDNA) has become a valuable analyte for molecular testing, but requires specialized collection tubes or immediate processing. We investigated the feasibility of using residual plasma from heparin separators, which are routinely used in clinical chemistry, as an accessible and underutilized source for cfDNA biobanking and testing. METHODSWe analyzed matched plasma samples from healthy volunteers in two experiments: an immediate-processing tube comparison across EDTA, Streck, and heparin separators (n = 5) and a clinical-handling simulation that paired EDTA and heparin separator tubes and delayed processing at room temperature versus 4{degrees}C (n = 6). We also analyzed matched EDTA and heparin separator plasma samples from viral PCR-positive patients (Hospital Cohort; n =38). Whole-genome sequencing and genome-wide enriched methylation sequencing were performed to evaluate concordance across multiple benchmarks, including metagenomics, chromosomal copy number, methylome, and fragmentomics. RESULTSUnder immediate processing, heparin separator plasma showed high concordance with EDTA and Streck plasma for methylation patterns (Spearmans {rho}=0.65-0.70) and fragmentation features (n = 5). In the clinical-handling simulation, cfDNA integrity in heparin separators was comparable to that in EDTA at 4{degrees}C (n=6). In the Hospital Cohort, heparin separators showed a strong concordance with matched EDTA tubes for viral detection (n=38, Spearmans {rho}=0.95), copy number alteration profiling (n=6, Spearmans {rho}=0.72-0.96), and methylation patterns (n=12, Spearmans {rho}=0.50-0.83). CONCLUSIONHospital residual plasma from routine clinical chemistry tests that are processed within a short pre-centrifugation window and refrigerated can provide a vast, untapped resource for cfDNA biobanking and potential testing.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.